JP2011512396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512396A5 JP2011512396A5 JP2010547259A JP2010547259A JP2011512396A5 JP 2011512396 A5 JP2011512396 A5 JP 2011512396A5 JP 2010547259 A JP2010547259 A JP 2010547259A JP 2010547259 A JP2010547259 A JP 2010547259A JP 2011512396 A5 JP2011512396 A5 JP 2011512396A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- sunitinib malate
- iii
- sunitinib
- dissolving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 30
- 229960002812 sunitinib malate Drugs 0.000 claims 29
- 239000002904 solvent Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 19
- 238000001816 cooling Methods 0.000 claims 12
- 239000007787 solid Substances 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 9
- 238000010438 heat treatment Methods 0.000 claims 9
- 239000000725 suspension Substances 0.000 claims 9
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 6
- 239000012296 anti-solvent Substances 0.000 claims 6
- 238000001035 drying Methods 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 235000011090 malic acid Nutrition 0.000 claims 6
- 239000001630 malic acid Substances 0.000 claims 6
- 229940099690 malic acid Drugs 0.000 claims 6
- 229960001796 sunitinib Drugs 0.000 claims 6
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 4
- 238000002411 thermogravimetry Methods 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 150000001298 alcohols Chemical class 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 150000002430 hydrocarbons Chemical class 0.000 claims 3
- 150000002576 ketones Chemical class 0.000 claims 3
- 239000003880 polar aprotic solvent Substances 0.000 claims 3
- 238000010992 reflux Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 150000008282 halocarbons Chemical class 0.000 claims 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 208000011645 metastatic carcinoma Diseases 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- -1 alkoxy alcohol Chemical compound 0.000 claims 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008096 xylene Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN314KO2008 | 2008-02-21 | ||
| PCT/GB2009/050170 WO2009104021A2 (en) | 2008-02-21 | 2009-02-20 | Novel polymorphs and processes for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011512396A JP2011512396A (ja) | 2011-04-21 |
| JP2011512396A5 true JP2011512396A5 (https=) | 2012-04-05 |
Family
ID=40466924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547259A Withdrawn JP2011512396A (ja) | 2008-02-21 | 2009-02-20 | 新規な多形およびその調製方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110112164A1 (https=) |
| EP (1) | EP2252607A2 (https=) |
| JP (1) | JP2011512396A (https=) |
| CN (1) | CN101983195A (https=) |
| AU (1) | AU2009215377A1 (https=) |
| CA (1) | CA2715657A1 (https=) |
| WO (1) | WO2009104021A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20063777B (en) | 2001-08-15 | 2006-03-27 | Upjohn Co | Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof |
| WO2010011834A2 (en) | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| EP2896618A1 (en) * | 2009-01-02 | 2015-07-22 | Hetero Research Foundation | Polymorphs of sunitinib malate |
| CA2774634A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
| EP2499133A2 (en) * | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
| US8916716B2 (en) | 2009-11-19 | 2014-12-23 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
| WO2011092664A1 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Crystalline forms of l-malic acid salt of sunitinib |
| WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
| CN103833733B (zh) * | 2012-11-21 | 2017-08-25 | 广东东阳光药业有限公司 | 一种替尼类药物新晶型 |
| PT3039424T (pt) | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
| CA2838587A1 (en) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation |
| US9278955B2 (en) | 2013-10-18 | 2016-03-08 | Sun Pharmaceutical Industries Limited | Ascorbic acid salt of sunitinib |
| CN104693187A (zh) * | 2013-12-10 | 2015-06-10 | 安杰世纪生物科技（北京）有限公司 | 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法 |
| CN105085490A (zh) * | 2014-05-09 | 2015-11-25 | 上海科胜药物研发有限公司 | 新的舒尼替尼苹果酸盐晶型及其制备方法 |
| WO2020216450A1 (en) | 2019-04-25 | 2020-10-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
| CN115057814A (zh) * | 2021-12-07 | 2022-09-16 | 山东新时代药业有限公司 | 一种米力农苹果酸盐晶体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1255752T1 (sl) * | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| GEP20063777B (en) * | 2001-08-15 | 2006-03-27 | Upjohn Co | Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof |
-
2009
- 2009-02-20 WO PCT/GB2009/050170 patent/WO2009104021A2/en not_active Ceased
- 2009-02-20 AU AU2009215377A patent/AU2009215377A1/en not_active Abandoned
- 2009-02-20 CA CA2715657A patent/CA2715657A1/en not_active Abandoned
- 2009-02-20 US US12/867,843 patent/US20110112164A1/en not_active Abandoned
- 2009-02-20 EP EP09713569A patent/EP2252607A2/en not_active Ceased
- 2009-02-20 CN CN2009801120563A patent/CN101983195A/zh active Pending
- 2009-02-20 JP JP2010547259A patent/JP2011512396A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512396A5 (https=) | ||
| JP2011512396A (ja) | 新規な多形およびその調製方法 | |
| TWI576344B (zh) | ５-氯-ｎ２-（２-異丙氧基-５-甲基-４-六氫吡啶-４-基-苯基）-ｎ４-［２-（丙烷-２-磺醯基）-苯基］-嘧啶-２，４-二胺之結晶型式 | |
| CN102453024B (zh) | 一种尼罗替尼盐酸盐晶型及其制备方法 | |
| JP2018520178A5 (https=) | ||
| HRP20141137T1 (hr) | Polimorfni oblici macrocikliäśkog inhibitora hcv | |
| CN102827153B (zh) | 阿齐沙坦的晶型及其制备方法 | |
| WO2012070062A2 (en) | Novel polymorph of nilotinib hydrochloride | |
| CN110862389A (zh) | 一种阿哌沙班晶型的制备方法 | |
| JP2011527330A5 (https=) | ||
| JP2011527330A (ja) | スニチニブリンゴ酸塩の結晶形の調製方法 | |
| CN102070618A (zh) | 一种化合物及其晶体 | |
| JP2022060192A5 (https=) | ||
| JP2013541589A5 (https=) | ||
| JP2010132561A (ja) | コハク酸シベンゾリンの新規ａ型結晶及びその製造方法 | |
| CN103524416B (zh) | 一种塞来昔布新晶型a及其制备方法 | |
| AU2012354150A1 (en) | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof | |
| CN103739568B (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 | |
| JP2015017137A (ja) | コハク酸シベンゾリンの新規ａ型結晶及びその製造方法 | |
| CN104098552A (zh) | 维拉佐酮的制备方法 | |
| TWI468391B (zh) | Ｎ－正丙基－３－（４－甲基苯基）－４－（４－甲磺醯基苯基）－２，５－二氫吡咯－２－酮的ｉ型結晶及其製造方法 | |
| ES2903091T3 (es) | Procedimiento de preparación de la forma cristalina hidratada B de Olaparib | |
| CN121554411A (zh) | 酒石酸西尼必利晶型及制备方法 | |
| CN103896926A (zh) | 二对甲苯磺酸拉帕替尼溶剂化物多晶型物及其制法和用途 | |
| CN103288740B (zh) | 一种高纯度硝酸异康唑的制备方法 |